-
Genetics and therapy type determine second cancer risk after childhood treatment
05/28/2025
Find out how polygenic risk scores and original treatment type contribute most to the risk of a developing a secondary cancer in childhood cancer survivors.
-
Research untangles role of stress granules in neurodegenerative disease
05/28/2025
See how ALS mutations to hnRNPA1 in stress granules drive fibril formation on condensate surfaces but fibrils grow from proteins in dilute phase
-
Research reveals unexpected roles of TEAD proteins in neurodevelopment
05/20/2025
Read new research showing TEAD proteins’ context can drive neural progenitor proliferation or differentiation, revealing risks for targeting these proteins.
-
St. Jude scientist Charles Mullighan elected to the Royal Society of London
05/20/2025
Prolific leukemia researcher named a Fellow of the elite 364-year-old British scientific organization selected for his genomic research into childhood ALL.
-
Infant immune systems respond differently to severe COVID-19
05/16/2025
Infants show unique immune responses to COVID-19, differing from adults and children. New study may guide better treatments for severe infant infections.
-
Study reveals targetable mechanism behind high-risk predisposition gene in pediatric medulloblastoma
05/15/2025
Uncover how ELP1 gene defects drive pediatric brain cancer—and learn how that revealed MDM2 inhibition as a targeted therapy to restore tumor suppressor p53.
-
St. Jude neurologist Richard Finkel named to TIME100 Health
05/08/2025
Dr. Richard Finkel, St. Jude Center for Experimental Neurotherapeutics director, recognized by TIME Magazine for influencing global health.
-
Researchers crack the code of cell movement
04/23/2025
New research found chemokines & G protein-coupled receptors encode cell migration information in small, disordered regions, and how to alter these proteins.
-
Roberts, Zhang receive prestigious appointments at AACR annual meeting
04/22/2025
St. Jude researchers and clinicians to be recognized for achievements in cancer research
-
Discovery of FOXR2 activation in various brain tumors refines diagnosis to improve care
04/15/2025
Read research showing activation of oncogene FOXR2 occurs in multiple pediatric central nervous system tumor types, with implications for clinical diagnosis.
Explore more research news
More Research News
-
Scientific Report
St. Jude Researchers, backed by extraordinary resources and support teams, are focused on making big discoveries.
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Peer-Reviewed Publications
Browse all scientific publications by St. Jude investigators.
-
Clinical & Research Innovation
At St. Jude, we dream big, and build our research programs to match. Explore just a few of the pioneering initiatives that make St. Jude different.
-
Research and Hospital Careers
Explore research and hospital careers at St. Jude. We offer rewarding job opportunities in scientific research, clinical care and business operations.
-
St. Jude Global
St. Jude Global is striving to create a network of programs and institutions to treat childhood diseases. Learn more about our newest initiatives.
-
Education and Training
St. Jude offers world-class scientific and clinical training experiences for fellows, students and other trainees. We also share knowledge through international outreach.
-
Pediatric Cancer Genome Project
Launched in 2010, the Pediatric Cancer Genome Project became the world’s most ambitious effort to discover the origins of pediatric cancer. Learn about its discoveries.